Scientific Steering Committee

triMS.online will allow for idea exchange on a global basis, particularly for individuals who are not often able to travel for scientific meetings

Laura Airas

triMS.online will enable participants to feel included, to contribute to the MS conversation early in their careers and to ask questions directly of experts.

Ari Green

triMS.online will help young neurologists and researchers to overcome barriers that often limit their ability to attend conferences

Gavin Giovannoni

Chair of Neurology, Barts and The London School of Medicine and Dentistry, UK and founder of triMS.online

Professor Giovannoni’s research is focussed on Epstein-Barr virus as a possible cause of MS, MS-related neurodegeneration, biomarker discovery, MS clinical outcome measures, MS clinical trials and immune tolerance strategies.

Laura Airas

Professor of Neuroimmunology, University of Turku, Finland

Professor Airas’s main interest is in pathological mechanisms of progressive MS. She was among the first in the world to apply PET imaging to the study of neuroinflammation in MS.

Reem Bunyan

Care Program, Vision Realization Office, Ministry of Health, and Director of the Model of Care Transformation Unit, Saudi Arabia

Dr Bunyan is an expert in paediatric MS. She previously studied at the Mayo Clinic, USA, where she completed a clinical fellowship in MS and autoimmune neurology.

Ari Green

Division Chief, Neuroimmunology and Glial Biology, Medical Director, Multiple Sclerosis and Neuroinflammation Center, Distinguished Professor of Neurology, Departments of Neurology and Ophthalmology, University of California San Francisco, CA, USA

Dr Green leads the research programme in Neuroimmunology and MS at UCSF. His lab focuses on developing reparative and remyelinating treatments for MS and related diseases, and establishing and biologically validating sensitive biomarkers for monitoring in MS.

Noriko Isobe

Associate Professor, Department of Neurological Therapeutics, Kyushu University, Japan

Dr Isobe’s current research interests include genetic susceptibility to MS, genetic determinants of disease progression in MS and T-cell receptor repertoires in MS.

Tomas Kalincik

Associate Professor and Head, Clinical Outcomes Research Unit, University of Melbourne, Australia and Head of the Royal Melbourne Hospital MS Centre, Australia

Dr Kalincik’s research interests span treatment outcomes in MS and neuromyelitis optica, individualized therapy, prognostics, epidemiology and utility of volumetric magnetic resonance imaging.

Farrah Mateen

Associate Professor of Neurology, Harvard Medical School, MA, USA

Dr Mateen leads a clinical trial funded by the National MS Society on light therapy for MS-related fatigue. Currently, she is the principal investigator of several multi-country studies.

Jiwon Oh

Assistant Professor of Medicine in the Division of Neurology at the University of Toronto, Ontario, Canada

Dr Oh’s research focuses on developing advanced MRI techniques in the spinal cord and brain for use in clinical settings. She is leading the Canadian National Progression Cohort, a prospective cohort study investigating progression in MS.

Julia Pakpoor

National Institute for Health Research Academic Clinical Fellow in Public Health at the University of Oxford, UK

Dr Pakpoor’s research is focused on using population-based data to explore risk factors for MS and the burden of neurodegenerative diseases on the health service.

Saúl Reyes Niño

Clinical Fellow, Barts and The London School of Medicine and Dentistry, Queen Mary University of London and the Department of Neurology, Barts and The London NHS Trust, UK

Dr Reyes’ research is focused on vaccination strategies in MS, the role of neurofilaments in clinical practice and the impact of social capital on the health outcomes of people with MS.